Search Result

Results for "

cGMP phosphodiesterase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Phosphodiesterase (PDE) (55) Adenosine Deaminase (3) Androgen Receptor (1) Calcium Channel (1) Drug Metabolite (2) Endogenous Metabolite (16) GPR35 (1) Influenza Virus (3) Isotope-Labeled Compounds (6) mAChR (1) MAPKAPK2 (MK2) (1) NO Synthase (6) Parasite (3) PKA (1) PKG (4) Potassium Channel (2) Reference Standards (9)
By Research Areas:	Cancer (13) Cardiovascular Disease (17) Endocrinology (22) Infection (8) Inflammation/Immunology (16) Metabolic Disease (13) Neurological Disease (17)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: Phosphodiesterase (PDE)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0442

Vardenafil 5 Publications Verification	Phosphodiesterase (PDE) Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Vardenafil is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B1816

Zaprinast 3 Publications Verification M&B 22948	Phosphodiesterase (PDE) GPR35	Cardiovascular Disease Neurological Disease Endocrinology
Zaprinast (M&B 22948) is a selective inhibitor of cGMP-selective Phosphodiesterase (PDE5). Zaprinast causes a significant increase in cGMP levels in myocytes. Zaprinast is a G protein-coupled receptor 35 (GPR35) agonist which activates rat GPR35 strongly and activates human GPR35 moderately. Zaprinast reduces vessel remodeling through antiproliferative and proapoptotic effects .

HY-103160A

EHNA hydrochloride 5 Publications Verification	Adenosine Deaminase Phosphodiesterase (PDE) Influenza Virus	Infection Cardiovascular Disease Neurological Disease Cancer
EHNA hydrochloride is a potent and selective dual inhibitor of *cyclic nucleotide phosphodiesterase* 2 (PDE2)(IC₅₀=4 μM) and adenosine deaminase (ADA)*. EHNA hydrochloride exerts a concentration inhibition of the cGMP-stimulated PDE II (cGs-PDE)(IC₅₀*:0.8 μM (human), 2 μM (porcine myocardium)), but has smaller inhibitory effect on the unstimulated PDE2 activity. EHNA hydrochloride play roles in mediating diverse pharmacological responses, including antiviral, antitumour and antiarrhythmic effects .

HY-18252

Avanafil 1 Publications Verification TA1790	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite	Cardiovascular Disease Endocrinology
Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-B0442A

Vardenafil hydrochloride 5 Publications Verification	Phosphodiesterase (PDE) Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Vardenafil hydrochloride is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-18253

Udenafil DA8159	Phosphodiesterase (PDE)	Endocrinology Cancer
Udenafil (DA8159) is a potent, selective and orally active phosphodiesterase type 5 (PDE5) inhibitor. Udenafil also inhibits cGMP hydrolysis and can be used for erectile dysfunction research .

HY-B0442B

Vardenafil hydrochloride trihydrate 5 Publications Verification	Endogenous Metabolite Phosphodiesterase (PDE)	Metabolic Disease Inflammation/Immunology Endocrinology
Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-N1860

3-O-Methylquercetin	Phosphodiesterase (PDE) NO Synthase	Infection Neurological Disease Inflammation/Immunology
3-O-Methylquercetin is an inhibitor of cAMP and CGMP-phosphodiesterase (PDE) with IC₅₀ at 13.8 μM and 14.3 μM, respectively. 3-O-Methylquercetin is an inhibitor of β-secretase with an IC₅₀ of 6.5 μM. 3-O-Methylquercetin has a neuroprotective effect against neuronal death caused by oxidative damage. 3-O-Methylquercetin has strong antiviral activity against poliovirus, coxsackie virus and human rhinovirus. 3-O-Methylquercetin has anti-inflammatory and trachea-relaxing effects and can be used in the study of inflammatory diseases and asthma .

HY-P2878

Phosphodiesterase I 1 Publications Verification PDE	Phosphodiesterase (PDE)	Neurological Disease Cancer
Phosphodiesterase I (PDE) is an enzyme that can catalyze the hydrolysis of the 3' ring phosphate bond of cyclic nucleotides, and is often used in biochemical research. Phosphodiesterase I acts as an important regulator of signal transduction mediated by the second messenger molecules cAMP and cGMP. According to their specificity to cyclic nucleotides, they can also be divided into different types, such as PDE1-PDE11, which also have certain potential in various diseases .

HY-B1639

Enoximone	Phosphodiesterase (PDE)	Cardiovascular Disease Inflammation/Immunology
Enoximone is an inotropic vasodilating agent and a selective and orally active phosphodiesterase III (PDE3) inhibitor with an IC₅₀ of 5.9 μM. Enoximone induces vasodilatation and increases intracellular levels of cAMP by inhibiting cGMP-inhibited PDE. Enoximone also exhibits PDE4 inhibitory effect with an IC₅₀ of 21.1 μM for myocardial PDE4A. Enoximone has the potential for congestive heart failure research and has bronchodilatory, antiasthma and anti-inflammatory effects .

HY-114672

MBCQ	Phosphodiesterase (PDE)	Cardiovascular Disease
MBCQ is a potent and selective cGMP-specific phosphodiesterase (PDE V; PDE5) inhibitor with an IC₅₀ of 19 nM. MBCQ lacks inhibitory activity toward other PDE isozymes (all IC₅₀s>100 μM). MBCQ dilates coronary arteries via specific inhibition of cGMP-PDE .

HY-108548

Rp-8-Br-PET-cGMPS sodium Rp-8-Bromo-PET-cGMPS	PKG	Inflammation/Immunology
Rp-8-Br-PET-cGMPS sodium (Rp-8-Bromo-PET-cGMPS) is an analog of cyclic GMP (cGMP). It is a cell permeable, competitive, and reversible inhibitor of cGMP-dependent protein kinases (cGKs) that blocks activation of cGKI and cGKII by cGMP (Kis=35 and 30 nM). It less potently inhibits protein kinase A (Ki=11 μM) and cGMP-induced activation of cyclic nucleotide-gated channels (IC₅₀=25 μM). In the absence of cGMP stimulation, Rp-8-bromo-PET-cGMPS can act as a partial agonist of cGKI (Ki=1 μM). Rp-8-bromo-PET-cGMPS is resistant to hydrolysis by phosphodiesterase 11.

HY-108619

Gisadenafil besylate UK 369003-26	Phosphodiesterase (PDE)	Neurological Disease
Gisadenafil besylate (UK 369003-26) is a specific, orally active phosphodiesterase 5 (PDE5) inhibitor with an IC₅₀ of 3.6 nM and prevents degradation of cyclic guanosine monophosphate (cGMP) .

HY-P2867

Phosphodiesterase II, Bovine Spleen 3′-Exonuclease	Phosphodiesterase (PDE)	Neurological Disease
Phosphodiesterase II (EC 3.1.16.1), namely phosphodiesterase 2, is mainly involved in the hydrolysis of the important second messengers cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), and is often used in biochemical research. Phosphodiesterase II is expressed in a variety of tissues, such as the adrenal medulla, brain, heart, platelets, macrophages and endothelial cells, and is involved in the regulation of many different intracellular processes .

HY-137108

Sp-8-pCPT-cGMPS	PKA PKG	Neurological Disease
Sp-8-pCPT-cGMPS is a potent cyclic guanosine monophosphate-gated channel agonist and a lipophilic activator of protein kinase G (types I α, I β, and II) and protein kinase A type II with excellent cell membrane permeability and phosphodiesterase stability. Sp-8-pCPT-cGMPS can be used to study the role of cGMP in neural plasticity and synaptic transmission .

HY-121381

Kuraridine	Phosphodiesterase (PDE)	Others
Kuraridine is a prenylated flavonol extract from the roots of Sophora flavescens. Kuraridine has an inhibitory effect on cGMP specific phosphodiesterase type 5 (PDE5) (IC₅₀=0.64 μM) .

HY-B0442AS

Vardenafil-d5 hydrochloride	Endogenous Metabolite Phosphodiesterase (PDE) Isotope-Labeled Compounds	Metabolic Disease Inflammation/Immunology Endocrinology
Vardenafil-d₅ hydrochloride is deuterated labeled Vardenafil hydrochloride (HY-B0442A). Vardenafil hydrochloride is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-131764

2'-O-MB-cGMP sodium 2′-O-Monobutyryl-cGMP sodium	Phosphodiesterase (PDE)	Others
2'-O-MB-cGMP (2′-O-Monobutyryl-cGMP) sodium is a cyclic GMP-specific phosphodiesterase inhibitor with an I₅₀ value of 35 µM. 2'-O-MB-cGMP (2′-O-Monobutyryl-cGMP) sodium inhibits Ca ²⁺ dependent phosphodiesterase hydrolysis using cAMP or cGMP as substrate .

HY-136520A

(R)-Xanthoanthrafil	Phosphodiesterase (PDE)	Metabolic Disease
(R)-Xanthoanthrafil is a phosphodiesterase-5 (PDE5) inhibitor. (R)-Xanthoanthrafil selectively inhibits PDE5, increasing cyclic guanosine monophosphate (cGMP) levels, leading to smooth muscle relaxation and promoting penile erection. (R)-Xanthoanthrafil can be used to study erectile dysfunction .

HY-14841

Gisadenafil UK-369003	Phosphodiesterase (PDE)	Neurological Disease
Gisadenafil (UK-369003) is a specific, orally active phosphodiesterase 5 (PDE5) inhibitor with an IC₅₀ of 3.6 nM and prevents degradation of cyclic guanosine monophosphate (cGMP) .

HY-114218

BL-122	Phosphodiesterase (PDE)	Cardiovascular Disease Inflammation/Immunology
BL-122 is a selective *phosphodiesterase-5* (PDE-5) inhibitor. BL-122 can increase the level of cGMP in the tissue, promote the expression of nitric oxide (NO), and mediate the relaxation of smooth muscle. BL-122 can be used for the researches of inflammation, immunology and cardiovascular disease, such as asthma and hypertension .

HY-18252A

Avanafil dibenzenesulfonate TA1790 dibenzenesulfonate	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite	Cardiovascular Disease Endocrinology
Avanafil (TA-1790) dibenzenesulfonate is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil dibenzenesulfonate activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil dibenzenesulfonate inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil dibenzenesulfonate can be used for the research of erectile dysfunction and osteoporosis .

HY-107022

BMS-341400	Phosphodiesterase (PDE)	Neurological Disease
BMS-341400 is an orally active selective phosphodiesterase 5 (PDE5) inhibitor with an IC₅₀ value of 0.3 nM. BMS-341400 reduces the degradation of cyclic guanosine monophosphate (cGMP), thereby enhancing nitric oxide (NO)-mediated relaxation of the smooth muscle of the corpus cavernosum and promoting erection. BMS-341400 can be used to study erectile dysfunction.

HY-117390

FR-181074	Phosphodiesterase (PDE)	Cardiovascular Disease Metabolic Disease
FR-181074 is a selective and orally active PDE V inhibitor. FR-181074 can specifically block PDE V to inhibit the degradation of cyclic guanosine monophosphate (cGMP) in order to relax smooth muscle. FR-181074 can be used for the researches of cardiovascular disease and endocrinology, such as hypertension and erectile dysfunction .

HY-N7648

Atherosperminine Atherospermine	Parasite Phosphodiesterase (PDE)	Infection
Atherosperminine (Atherospermine) is a phosphodiesterase inhibitor. Atherosperminine inhibits growth of chloroquine-resistant Plasmodium falciparum. Atherosperminine scavenges DPPH free radicals, exhibits ferric reducing power, and chelates metal ions. Atherosperminine can be used for the research of malaria .

HY-103160B

EHNA	Adenosine Deaminase Phosphodiesterase (PDE) Influenza Virus	Infection Cardiovascular Disease Neurological Disease Cancer
EHNA is a potent and selective dual inhibitor of *cyclic nucleotide phosphodiesterase* 2 (PDE2)(IC₅₀=4 μM) and adenosine deaminase (ADA)*. EHNA exerts a concentration inhibition of the cGMP-stimulated PDE II (cGs-PDE)(IC₅₀*:0.8 μM (human), 2 μM (porcine myocardium)), but has smaller inhibitory effect on the unstimulated PDE2 activity. EHNA play roles in mediating diverse pharmacological responses, including antiviral, antitumour and antiarrhythmic effects .

HY-105349

T-0156	Phosphodiesterase (PDE)	Neurological Disease
T-0156 is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor. T-0156 specifically inhibits the hydrolysis of cyclic guanosine monophosphate (cGMP) by PDE5 in a competitive manner (IC₅₀=0.23 nM). T-0156 inhibits PDE6 (IC₅₀=56 nM) and has low potencies against PDE1, PDE2, PDE3, and PDE4 (IC₅₀>10 μM). T-0156 enhances the nitric oxide (NO)/cGMP pathway .

HY-164685

T-0156 free base	Phosphodiesterase (PDE)	Neurological Disease
T-0156 free base is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor. T-0156 free base specifically inhibits the hydrolysis of cyclic guanosine monophosphate (cGMP) by PDE5 in a competitive manner (IC₅₀=0.23 nM). T-0156 free base inhibits PDE6 (IC₅₀=56 nM) and has low potencies against PDE1, PDE2, PDE3, and PDE4 (IC₅₀>10 μM). T-0156 free base enhances the nitric oxide (NO)/cGMP pathway .

HY-120684

PDE10-IN-6	Phosphodiesterase (PDE)	Others
PDE10-IN-6 is a phosphodiesterase-10 inhibitor that inhibits the breakdown of cAMP and cGMP, thereby slowing or halting their hydrolysis.

HY-137633

Sp-8-Br-PET-cGMPS	PKG	Neurological Disease
Sp-8-Br-PET-cGMPS is a membrane-permeable PKG agonist and a membrane-permeable inhibitor of retinal-type cGMP-gated ion channels, as well as an activator of cGMP-dependent protein kinases I α and I β. Sp-8-Br-PET-cGMPS is resistant to mammalian cyclic nucleotide-dependent phosphodiesterases, has no metabolic side effects, and is more lipophilic and permeable than Sp-8-pCPT-cGMPS. Sp-8-Br-PET-cGMPS can be used to study the role of cGMP signaling pathways in the nervous system .

HY-B0442C

Vardenafil dihydrochloride	Endogenous Metabolite Phosphodiesterase (PDE)	Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Vardenafil dihydrochloride is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM respectively, while IC₅₀s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^- .

HY-B0442S

Vardenafil-d5	Isotope-Labeled Compounds Phosphodiesterase (PDE) Endogenous Metabolite	Endocrinology
Vardenafil-d₅ is deuterium labeled Vardenafil. Vardenafil is a selective, orally active, potent inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows selectivity over PDE1 (180 nM), PDE6 (11 nM), PDE2, PDE3, and PDE4 (>1000 nM). Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil can be used for the research of erectile dysfunction .

HY-114643

(Rac)-Tovinontrine (Rac)-IMR-687	Phosphodiesterase (PDE)	Cardiovascular Disease
(Rac)-Tovinontrine ((Rac)-IMR-687) is a phosphodiesterase 9 (PDE9) inhibitor that increases cyclic guanosine monophosphate (cGMP) levels. (Rac)-Tovinontrine is promising for research of thalassemia .

HY-129210

KMUP-4	Phosphodiesterase (PDE) Potassium Channel	Cardiovascular Disease
KMUP-4, as a xanthine derivative with cGMP-enhancing activity, induces aortic relaxation through endothelium-dependent and independent mechanisms. KMUP-4 increases cytoplasmic cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP) levels by inhibiting *phosphodiesterases* (PDEs) and activating K ⁺ channels. KMUP-4 can be used in the study of cardiovascular diseases .

HY-18252R

Avanafil (Standard) TA1790 (Standard)	Reference Standards Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite	Cardiovascular Disease Endocrinology
Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-B0442CR

Vardenafil dihydrochloride (Standard)	Reference Standards Endogenous Metabolite Phosphodiesterase (PDE)	Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Vardenafil (dihydrochloride) (Standard) is the analytical standard of Vardenafil (dihydrochloride). This product is intended for research and analytical applications. Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM respectively, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-B0442AR

Vardenafil hydrochloride (Standard)	Phosphodiesterase (PDE) Endogenous Metabolite Reference Standards	Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Vardenafil (hydrochloride) (Standard) is the analytical standard of Vardenafil (hydrochloride). This product is intended for research and analytical applications. Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-B0442R

Vardenafil (Standard)	Reference Standards Phosphodiesterase (PDE) Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Endocrinology
Vardenafil (Standard) is the analytical standard of Vardenafil. This product is intended for research and analytical applications. Vardenafil is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-W049735R

N,N,O-Tridesmethylvenlafaxine (Standard)	Drug Metabolite Reference Standards Endogenous Metabolite	Metabolic Disease
Vardenafil (dihydrochloride) (Standard) is the analytical standard of Vardenafil (dihydrochloride). This product is intended for research and analytical applications. Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM respectively, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-106477

Quazinone Ro 13-6438; Ro 13-6438/006	Phosphodiesterase (PDE) MAPKAPK2 (MK2)	Infection
Quazinone is a selective inhibitor of cGMP-inhibited-phosphodiesterase (cGI-PDE, PDE3). Quazinone inhibits the phosphorylation of p42/p44 MAP kinase. Quazinone possesses antimitogenic effect .

HY-B0442BR

Vardenafil hydrochloride trihydrate (Standard)	Reference Standards Endogenous Metabolite Phosphodiesterase (PDE)	Metabolic Disease Inflammation/Immunology Endocrinology
Vardenafil (hydrochloride trihydrate) (Standard) is the analytical standard of Vardenafil (hydrochloride trihydrate). This product is intended for research and analytical applications. Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-18252S3

Avanafil-13C5 TA1790-¹³C₅	Isotope-Labeled Compounds Endogenous Metabolite Phosphodiesterase (PDE) NO Synthase	Cardiovascular Disease Endocrinology
Avanafil- ¹³C₅ (TA1790- ¹³C₅) is ¹³C labeled Avanafil. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-18252S1

Avanafil-13C5,15N,d2	Endogenous Metabolite NO Synthase Phosphodiesterase (PDE) Isotope-Labeled Compounds	Cardiovascular Disease Endocrinology
Avanafil- ¹³C₅, ¹⁵N,d₂ is ¹⁵N and deuterated labeled Avanafil (HY-18252). Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-101826A

ER21355 hydrochloride	Phosphodiesterase (PDE)	Cancer
ER21355 hydrochloride is the hydrochloride form of ER21355 (HY-101826). ER21355 hydrochloride is an inhibitor for phosphodiesterase (PDE), which is potent for ameliorating benign prostatic hyperplasia (BPH) and prostatism through increasing levels of cAMP and cGMP, and resulting a relaxation of the smooth muscle cell .

HY-18253S

Udenafil-d7	Isotope-Labeled Compounds Phosphodiesterase (PDE)	Others Endocrinology
Udenafil-d₇ is the deuterium labeled Udenafil. Udenafil (DA8159) is a potent, selective and orally active phosphodiesterase type 5 (PDE5) inhibitor. Udenafil also inhibits cGMP hydrolysis and can be used for erectile dysfunction research .

HY-18253R

Udenafil (Standard) DA8159 (Standard)	Reference Standards Phosphodiesterase (PDE)	Endocrinology Cancer
Udenafil (Standard) is the analytical standard of Udenafil. This product is intended for research and analytical applications. Udenafil (DA8159) is a potent, selective and orally active phosphodiesterase type 5 (PDE5) inhibitor. Udenafil also inhibits cGMP hydrolysis and can be used for erectile dysfunction research .

HY-170431

SAL-0010042	Phosphodiesterase (PDE) Parasite	Infection
SAL-0010042 is the inhibitor for Plasmodium phosphodiesterase β (PDEβ), that inhibits the hydrolysis of cAMP and cGMP (IC₅₀=48.9 nM) in gametocytes, activates PKG, and inhibits the growth and development of Plasmodium (IC₅₀ for 3D7 and Dd2 is 142 nM and 218 nM). SAL-0010042 inhibits hPDE5 and hPDE6 with IC₅₀ of 632 nM and 73 nM .

HY-107022A

BMS-341400 mesylate	Phosphodiesterase (PDE)	Neurological Disease
BMS-341400 mesylate is a selective phosphodiesterase 5 (PDE5) inhibitor with an IC₅₀ value of 0.3 nM. BMS-341400 mesylate reduces the degradation of cyclic guanosine monophosphate (cGMP), thereby enhancing nitric oxide (NO)-mediated relaxation of the smooth muscle of the corpus cavernosum and promoting erection. BMS-341400 mesylate can be used to study erectile dysfunction .

HY-147946

PDE1-IN-4	Phosphodiesterase (PDE) Calcium Channel	Inflammation/Immunology
PDE1-IN-4 (compound 2g) is a potent and selective PDE1 (phosphodiesterase-1) inhibitor, with IC₅₀ values of 10, 145, and 354 nM for PDE1C, PDE1A, and PDE1B, respectively. PDE1-IN-4 inhibits myofibroblast differentiation of human lung fibroblasts induced by TGF-β1. PDE1-IN-4 shows anti-fibrosis effects through the regulation of cAMP (3′,5′-cyclic adenosine monophosphate) and cGMP (3′,5′-cyclic guanosine monophosphate). PDE1-IN-4 can be used for idiopathic pulmonary fibrosis (IPF) research .

HY-173640

ID11916	Androgen Receptor Phosphodiesterase (PDE)	Cancer
ID11916 is an orally active androgen receptor (AR) antagonist and a phosphodiesterase 5 (PDE5) inhibitor. ID11916 blocks androgen binding to AR, nuclear translocation, and androgen-dependent transcriptional activity of AR, while increasing intracellular cGMP levels and activating PKG via inhibition. ID11916 shows potent anti-cancer effect in prostate cancer cell lines VCaP and 22Rv1 and in AR-positive breast cancer cell lines SK-BR-3 .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0442

Vardenafil 5 Publications Verification	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-18252

Avanafil 1 Publications Verification TA1790	Cardiovascular Disease Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-B0442A

Vardenafil hydrochloride 5 Publications Verification	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil hydrochloride is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B0442B

Vardenafil hydrochloride trihydrate 5 Publications Verification	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-N1860

3-O-Methylquercetin	Flavonoids Classification of Application Fields Flavones Aconitum apetalum (Huth) B. Fedtsch. Plants Rhamnaceae Inflammation/Immunology Disease Research Fields	Phosphodiesterase (PDE) NO Synthase
3-O-Methylquercetin is an inhibitor of cAMP and CGMP-phosphodiesterase (PDE) with IC₅₀ at 13.8 μM and 14.3 μM, respectively. 3-O-Methylquercetin is an inhibitor of β-secretase with an IC₅₀ of 6.5 μM. 3-O-Methylquercetin has a neuroprotective effect against neuronal death caused by oxidative damage. 3-O-Methylquercetin has strong antiviral activity against poliovirus, coxsackie virus and human rhinovirus. 3-O-Methylquercetin has anti-inflammatory and trachea-relaxing effects and can be used in the study of inflammatory diseases and asthma .

HY-121381

Kuraridine	Chalcones Flavonoids Classification of Application Fields Leguminosae Other Diseases Phenols Polyphenols Sophora flavescens Aiton Plants Disease Research Fields Source Classification	Phosphodiesterase (PDE)
Kuraridine is a prenylated flavonol extract from the roots of Sophora flavescens. Kuraridine has an inhibitory effect on cGMP specific phosphodiesterase type 5 (PDE5) (IC₅₀=0.64 μM) .

HY-18252A

Avanafil dibenzenesulfonate TA1790 dibenzenesulfonate	Cardiovascular Disease Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
Avanafil (TA-1790) dibenzenesulfonate is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil dibenzenesulfonate activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil dibenzenesulfonate inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil dibenzenesulfonate can be used for the research of erectile dysfunction and osteoporosis .

HY-N7648

Atherosperminine Atherospermine	Infection Alkaloids Structural Classification Classification of Application Fields Other Alkaloids Fissistigma glaucescens Plants Annonaceae Disease Research Fields Source Classification	Parasite Phosphodiesterase (PDE)
Atherosperminine (Atherospermine) is a phosphodiesterase inhibitor. Atherosperminine inhibits growth of chloroquine-resistant Plasmodium falciparum. Atherosperminine scavenges DPPH free radicals, exhibits ferric reducing power, and chelates metal ions. Atherosperminine can be used for the research of malaria .

HY-B0442C

Vardenafil dihydrochloride	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil dihydrochloride is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM respectively, while IC₅₀s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^- .

HY-18252R

Avanafil (Standard) TA1790 (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-B0442CR

Vardenafil dihydrochloride (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil (dihydrochloride) (Standard) is the analytical standard of Vardenafil (dihydrochloride). This product is intended for research and analytical applications. Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM respectively, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-B0442AR

Vardenafil hydrochloride (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Phosphodiesterase (PDE) Endogenous Metabolite Reference Standards
Vardenafil (hydrochloride) (Standard) is the analytical standard of Vardenafil (hydrochloride). This product is intended for research and analytical applications. Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-B0442R

Vardenafil (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil (Standard) is the analytical standard of Vardenafil. This product is intended for research and analytical applications. Vardenafil is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-W049735R

N,N,O-Tridesmethylvenlafaxine (Standard)	Monophenols Phenols Endogenous metabolite Source Classification	Drug Metabolite Reference Standards Endogenous Metabolite
Vardenafil (dihydrochloride) (Standard) is the analytical standard of Vardenafil (dihydrochloride). This product is intended for research and analytical applications. Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM respectively, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-B0442BR

Vardenafil hydrochloride trihydrate (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil (hydrochloride trihydrate) (Standard) is the analytical standard of Vardenafil (hydrochloride trihydrate). This product is intended for research and analytical applications. Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-113972R

Methyl mycophenolate (Standard)	Structural Classification Monophenols Microorganisms Marine natural products Phenols Marine microorganism	Reference Standards Others
Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-N7648A

Atherosperminine hydrochloride Atherospermine hydrochloride	Structural Classification Alkaloids Other Alkaloids Plants Lauraceae Cryptocarya nigra Kosterm. Source Classification	Parasite Phosphodiesterase (PDE)
Atherosperminine (Atherospermine) hydrochloride is a phosphodiesterase inhibitor. Atherosperminine hydrochloride inhibits growth of chloroquine-resistant Plasmodium falciparum. Atherosperminine hydrochloride scavenges DPPH free radicals, exhibits ferric reducing power, and chelates metal ions. Atherosperminine hydrochloride can be used for the research of malaria .

Species:	Human (4) Mouse (1)
Tag:	His (5) Myc (1) GST (2)
Source:	Sf9 insect cells (3) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P71591

	cGB-PDE Protein, Mouse (Myc, His) Pde5a; Pde5; cGMP-specific 3',5'-cyclic phosphodiesterase; EC 3.1.4.35; cGMP-binding cGMP-specific phosphodiesterase; CGB-PDE	Mouse	E. coli
	cGB-PDE protein regulates signal transduction by specifically hydrolyzing cto 5'-GMP, thereby controlling the intracellular concentration of cyclic nucleotides, particularly nitric-oxide-generated cGMP. cGB-PDE Protein, Mouse (Myc, His) is the recombinant mouse-derived cGB-PDE protein, expressed by E. coli , with N-His, C-Myc labeled tag.

HY-P74647

	PDE2A Protein, Human (sf9, His) cGMP-dependent 3',5'-cyclic phosphodiesterase; CGS-PDE; PDE2A	Human	Sf9 insect cells
	PDE2A is a cGMP-activated cyclic nucleotide phosphodiesterase that exhibits dual specificity for the second messengers cAMP and cGMP, key regulators in various physiological processes. PDE2A exhibits higher efficiency by covering cAMP and plays an important role in cell growth and migration. PDE2A Protein, Human (sf9, His) is the recombinant human-derived PDE2A protein, expressed by Sf9 insect cells , with C-His labeled tag.

HY-P75963

	PDE9A Protein, Human (His) High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A; PDE9A	Human	E. coli
	PDE9A is a phosphodiesterase that uniquely hydrolyzes second messengers with unparalleled specificity, particularly in the regulation of natriuretic peptide-dependent signaling in the heart, which is critical for the control of cardiac hypertrophy. Its specificity rules out effects on nitric oxide-dependent signaling in the heart. PDE9A Protein, Human (His) is the recombinant human-derived PDE9A protein, expressed by E. coli , with N-His labeled tag.

HY-P75961

	PDE3A Protein, Human (sf9, His-GST) cGMP-inhibited 3',5'-cyclic phosphodiesterase A; CGI-PDE A; PDE3A	Human	Sf9 insect cells
	PDE3A protein, a cyclic nucleotide phosphodiesterase, targets cAMP, cGMP, and cUMP, crucial in diverse physiological processes. In an E2/17beta-estradiol-induced pro-apoptotic pathway, E2 stabilizes the PDE3A/SLFN12 complex, leading to SLFN12 dephosphorylation and activating its pro-apoptotic ribonuclease activity. This pathway is implicated in tissues with high E2 concentrations, potentially contributing to processes like placenta remodeling. PDE3A Protein, Human (sf9, His-GST) is the recombinant human-derived PDE3A protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

HY-P75962

	PDE9A Protein, Human (sf9, His-GST) High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A; PDE9A	Human	Sf9 insect cells
	PDE9A is a phosphodiesterase that uniquely hydrolyzes second messengers with unparalleled specificity, particularly in the regulation of natriuretic peptide-dependent signaling in the heart, which is critical for the control of cardiac hypertrophy. Its specificity rules out effects on nitric oxide-dependent signaling in the heart. PDE9A Protein, Human (sf9, His-GST) is the recombinant human-derived PDE9A protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-B0442AS

Vardenafil-d5 hydrochloride

Vardenafil-d₅ hydrochloride is deuterated labeled Vardenafil hydrochloride (HY-B0442A). Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B0442S

Vardenafil-d5

Vardenafil-d₅ is deuterium labeled Vardenafil. Vardenafil is a selective, orally active, potent inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows selectivity over PDE1 (180 nM), PDE6 (11 nM), PDE2, PDE3, and PDE4 (>1000 nM). Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil can be used for the research of erectile dysfunction .

HY-18252S3

Avanafil-13C5

Avanafil- ¹³C₅ (TA1790- ¹³C₅) is ¹³C labeled Avanafil. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-18252S1

Avanafil-13C5,15N,d2

Avanafil- ¹³C₅, ¹⁵N,d₂ is ¹⁵N and deuterated labeled Avanafil (HY-18252). Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-18253S

Udenafil-d7
Udenafil-d₇ is the deuterium labeled Udenafil. Udenafil (DA8159) is a potent, selective and orally active phosphodiesterase type 5 (PDE5) inhibitor. Udenafil also inhibits cGMP hydrolysis and can be used for erectile dysfunction research .

HY-14841S

Gisadenafil-d5
Gisadenafil-d₅ (UK-369003-d₅) is the deuterium labeled Gisadenafil (HY-14841). Gisadenafil (UK-369003) is a specific, orally active phosphodiesterase 5 (PDE5) inhibitor with an IC₅₀ of 3.6 nM and prevents degradation of cyclic guanosine monophosphate (cGMP) .

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P87358

	PDE10A Antibody (YA7041) 5''-cyclic phosphodiesterase 10A antibody; cAMP and cAMP inhibited cGMP 3'5' cyclic phosphodiesterase 10A antibody; cAMP and cAMP-inhibited cGMP 3'' antibody; FLJ11894 antibody; HSPDE 10A antibody; HSPDE10A antibody; PDE 10A antibody; PDE10_HUMAN antibody; Pde10a antibody; phosphodiesterase 10A antibody	WB, IHC-P, FC	Human, Mouse, Rat
	PDE10A Antibody (YA7041) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PDE10A.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks